210 related articles for article (PubMed ID: 34127734)
1. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
[TBL] [Abstract][Full Text] [Related]
2. Drug combination screening as a translational approach toward an improved drug therapy for chordoma.
Scheipl S; Barnard M; Lohberger B; Zettl R; Brcic I; Liegl-Atzwanger B; Rinner B; Meindl C; Fröhlich E
Cell Oncol (Dordr); 2021 Dec; 44(6):1231-1242. PubMed ID: 34550531
[TBL] [Abstract][Full Text] [Related]
3. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.
Jäger D; Barth TFE; Brüderlein S; Scheuerle A; Rinner B; von Witzleben A; Lechel A; Meyer P; Mayer-Steinacker R; Baer AV; Schultheiss M; Wirtz CR; Möller P; Mellert K
Sci Rep; 2017 May; 7(1):2032. PubMed ID: 28515451
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development.
Ekert JE; Johnson K; Strake B; Pardinas J; Jarantow S; Perkinson R; Colter DC
PLoS One; 2014; 9(3):e92248. PubMed ID: 24638075
[TBL] [Abstract][Full Text] [Related]
6. UM-Chor1: establishment and characterization of the first validated clival chordoma cell line.
Owen JH; Komarck CM; Wang AC; Abuzeid WM; Keep RF; McKean EL; Sullivan S; Fan X; Prince MEP
J Neurosurg; 2018 Mar; 128(3):701-709. PubMed ID: 28430034
[TBL] [Abstract][Full Text] [Related]
7. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
Yang C; Yong L; Liang C; Li Y; Ma Y; Wei F; Jiang L; Zhou H; He G; Pan X; Hai B; Wu J; Xu Y; Liu Z; Liu X
Oncogene; 2020 Jun; 39(24):4711-4727. PubMed ID: 32404987
[TBL] [Abstract][Full Text] [Related]
8. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
Kentsis A; Reed C; Rice KL; Sanda T; Rodig SJ; Tholouli E; Christie A; Valk PJ; Delwel R; Ngo V; Kutok JL; Dahlberg SE; Moreau LA; Byers RJ; Christensen JG; Vande Woude G; Licht JD; Kung AL; Staudt LM; Look AT
Nat Med; 2012 Jul; 18(7):1118-22. PubMed ID: 22683780
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.
Chattopadhyay C; Grimm EA; Woodman SE
PLoS One; 2014; 9(2):e83957. PubMed ID: 24551032
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
12. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
13. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.
Ostroumov E; Hunter CJ
Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584
[TBL] [Abstract][Full Text] [Related]
14. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.
Magnaghi P; Salom B; Cozzi L; Amboldi N; Ballinari D; Tamborini E; Gasparri F; Montagnoli A; Raddrizzani L; Somaschini A; Bosotti R; Orrenius C; Bozzi F; Pilotti S; Galvani A; Sommer J; Stacchiotti S; Isacchi A
Mol Cancer Ther; 2018 Mar; 17(3):603-613. PubMed ID: 29237806
[TBL] [Abstract][Full Text] [Related]
15. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
Li Y; Huang X; Zhang J; Li Y; Ma K
Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
[TBL] [Abstract][Full Text] [Related]
17. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
18. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
[TBL] [Abstract][Full Text] [Related]
19. Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.
Rinner B; Froehlich EV; Buerger K; Knausz H; Lohberger B; Scheipl S; Fischer C; Leithner A; Guelly C; Trajanoski S; Szuhai K; Liegl B
Int J Oncol; 2012 Feb; 40(2):443-51. PubMed ID: 22002331
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
